These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35976998)

  • 1. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease.
    Venkataraman AV; Mansur A; Rizzo G; Bishop C; Lewis Y; Kocagoncu E; Lingford-Hughes A; Huiban M; Passchier J; Rowe JB; Tsukada H; Brooks DJ; Martarello L; Comley RA; Chen L; Schwarz AJ; Hargreaves R; Gunn RN; Rabiner EA; Matthews PM
    Sci Transl Med; 2022 Aug; 14(658):eabk1051. PubMed ID: 35976998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease.
    Terada T; Therriault J; Kang MS; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Poltronetti NM; Ottoy J; Arias JF; Bezgin G; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Eur J Neurol; 2022 May; 29(5):1324-1334. PubMed ID: 35007366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Mecca AP; Chen MK; O'Dell RS; Naganawa M; Toyonaga T; Godek TA; Harris JE; Bartlett HH; Zhao W; Nabulsi NB; Wyk BCV; Varma P; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2020 Jul; 16(7):974-982. PubMed ID: 32400950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain:
    Mansur A; Rabiner EA; Comley RA; Lewis Y; Middleton LT; Huiban M; Passchier J; Tsukada H; Gunn RN;
    J Nucl Med; 2020 Jan; 61(1):96-103. PubMed ID: 31324712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
    Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
    Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of ischemia-induced impairment of mitochondrial complex I function in monkey brain.
    Tsukada H; Ohba H; Nishiyama S; Kanazawa M; Kakiuchi T; Harada N
    J Cereb Blood Flow Metab; 2014 Apr; 34(4):708-14. PubMed ID: 24447952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic vesicle glycoprotein 2A (SV2A) levels in the cerebral cortex in patients with Alzheimer's disease: a radioligand binding study in postmortem brains.
    Mikkelsen JD; Kaad S; Aripaka SS; Finsen B
    Neurobiol Aging; 2023 Sep; 129():50-57. PubMed ID: 37269646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease.
    Terada T; Obi T; Bunai T; Matsudaira T; Yoshikawa E; Ando I; Futatsubashi M; Tsukada H; Ouchi Y
    Neurology; 2020 Apr; 94(15):e1592-e1604. PubMed ID: 32139504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.
    Terada T; Therriault J; Kang MSP; Savard M; Pascoal TA; Lussier F; Tissot C; Wang YT; Benedet A; Matsudaira T; Bunai T; Obi T; Tsukada H; Ouchi Y; Rosa-Neto P
    Mol Neurodegener; 2021 Apr; 16(1):28. PubMed ID: 33902654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial spin labeling versus
    Dolui S; Li Z; Nasrallah IM; Detre JA; Wolk DA
    Neuroimage Clin; 2020; 25():102146. PubMed ID: 31931403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
    Wilson H; Pagano G; de Natale ER; Mansur A; Caminiti SP; Polychronis S; Middleton LT; Price G; Schmidt KF; Gunn RN; Rabiner EA; Politis M
    Mov Disord; 2020 Aug; 35(8):1416-1427. PubMed ID: 32347983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease.
    Yan L; Liu CY; Wong KP; Huang SC; Mack WJ; Jann K; Coppola G; Ringman JM; Wang DJJ
    Neuroimage Clin; 2018; 17():751-760. PubMed ID: 29527482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease.
    Musiek ES; Chen Y; Korczykowski M; Saboury B; Martinez PM; Reddin JS; Alavi A; Kimberg DY; Wolk DA; Julin P; Newberg AB; Arnold SE; Detre JA
    Alzheimers Dement; 2012 Jan; 8(1):51-9. PubMed ID: 22018493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial volume correction analysis for
    Lu Y; Toyonaga T; Naganawa M; Gallezot JD; Chen MK; Mecca AP; van Dyck CH; Carson RE
    Neuroimage; 2021 Sep; 238():118248. PubMed ID: 34119639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and
    Riederer I; Bohn KP; Preibisch C; Wiedemann E; Zimmer C; Alexopoulos P; Förster S
    Radiology; 2018 Jul; 288(1):198-206. PubMed ID: 29762090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired cerebral blood flow in type 2 diabetes mellitus - A comparative study with subjective cognitive decline, vascular dementia and Alzheimer's disease subjects.
    Chau ACM; Cheung EYW; Chan KH; Chow WS; Shea YF; Chiu PKC; Mak HKF
    Neuroimage Clin; 2020; 27():102302. PubMed ID: 32521474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.